While pan‐HDAC degraders could be developed to treat multiple cancers,[51] selective HDAC6 PROTACs, like selective HDAC6 inhibitors,[55] could be used in neurodegenerative diseases, inflammatory diseases, and some cancers. Here, HDAC9 is linked to cancer.